Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tile Shop Holdings

UnitedHealth Group

Eli Lilly, UnitedHealth and Tile Shop are included in this Analyst Blog.

The Zacks Analyst Blog Eli Lilly, UnitedHealth and Tile Shop

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885.

This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges

Digital Realty Trust

Equinix

NVIDIA

Novo Nordisk

Occidental Petroleum

Taiwan Semiconductor Manufacturing

Investors should look for top-quality stocks for the remainder of the year. With plenty of uncertainties, a nearing presidential election, geopolitical issues, and a lack of a clear economic trajectory, you want to make sure the stock you're jumping into is top-quality and fundamentally solid.

7 Top-Quality Stocks to Buy Now: July 2024

Tesla

Eli Lilly's blockbuster new weight-loss treatment is helping to drive a $130 billion anti-obesity market. Electric vehicles, self-driving taxis, and humanoid robots give Tesla's shareholders multiple ways to win.

2 Unstoppable Growth Stocks to Buy and Hold for the Next Decade

Advanced Micro Devices

Chevron

Netflix

Oracle

Visa

Billion-dollar companies are some of the most valuable companies. They lead the stock market and have become an integral part of the economy.

7 Billion-Dollar Stocks That Deserve a Spot in Your Portfolio

American Tower

Broadcom

The best way to get rich is not through get-rich quick schemes — slow and steady wins the race. It is not something to achieve in a single quarter or even a year.

3 Stocks for Patient Investors Looking to Build Generational Wealth

Dutch Bros

Eli Lilly just garnered another approval that could change the trajectory of future growth for the storied company. Dutch Bros is opening new locations and improving profitability, while maintaining a strategic focus on growth.

2 High-Flying Growth Stocks You Can Buy Right Now Before They Surge Even Higher

Eli Lilly stock has soared, but investment bank analysts who follow the drugmaker think it can climb higher. According to electronic health records, Eli Lilly's drug for chronic weight management is outperforming the competition.

Is Eli Lilly a Good Dividend Stock to Buy Now?

Researchers compared the effectiveness of Novo Nordisk and Eli Lilly's weight loss drugs. Patients stopped treatment with both at high rates.

This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock

American Express

Bank of America

Brown & Brown

Carlisle Companies

Cintas Corp

Dick's Sporting Goods

Comfort Systems USA

Hess Midstream Partners

Hartford Financial Services Group

Hamilton Lane

Microsoft

NRG Energy

NetApp

Owens Corning

QUALCOMM

Tetra Tech

Wingstop

This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks: July 2024

Apple

D.R. Horton

Starbucks

Schlumberger

Walmart

Earnings season is a combination report card and progress report. The headline results tell investors what already happened.

The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off

Dell Technologies

If you don't own at least one of the Magnificent Seven technology titans, odds are you're probably trailing the S&P 500 by a wide margin. Indeed, beating the market is tough without some help from the technology sector's biggest, brightest stars.

3 Powerful Stocks Worthy of Magnificent 7 Status

The Food and Drug Administration recently approved Kisunla as a treatment for early symptomatic Alzheimer's disease. Despite the news, shares of Eli Lilly didn't take off.

Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.

Eli Lilly and Novo Nordisk compete in the diabetes and obesity care markets. Outside of weight loss, Lilly also has a strong portfolio of medicines used in cancer, plaque psoriasis, and more.

Did Eli Lilly Just Get a Leg Up on Novo Nordisk?

In the aftermath of Nvidia's (NASDAQ: NVDA ) historic trillion-dollar run, investors are scrambling to find the next potential trillion-dollar stocks to join the club. Quite a few contenders are nearing the mark regarding valuations, but the market cap isn't everything.

The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now

Eli Lilly has earned approval for an Alzheimer's disease therapy. It's yet another blockbuster drug for its lineup.

Should You Buy Eli Lilly Stock After Another Major Win?

Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs.

Will Wall Street Darling Eli Lilly's Stock Split Next?

Jefferies Financial Group Inc

Even in the future, blue-chip stocks will be among the most reliable of all the available stocks. That's because they belong to businesses and companies with solid financials and growth potential.

3 Future Blue-Chip Stocks That Could Make You Rich

Pfizer

We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly.

Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick?

Vanguard Growth ETF

Growth stocks have been in the spotlight since 1995. This year, Eli Lilly and the Vanguard Growth Index Fund ETF Shares have been top performers in the category.

Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares

JPMorgan Chase & Co

Exxon Mobil

CNCB's Jim Cramer on Wednesday reviewed eight stocks that could join the coveted "trillion-dollar stock club," pinpointing Eli Lilly and Tesla as top contenders. Also on the list are Berkshire Hathaway, JPMorgan, Broadcom, Walmart, Visa and Exxon Mobil.

Jim Cramer reviews 8 companies that could top $1 trillion in market cap

News for Eli Lilly Stock (LLY)